A multi-center randomized, double-blind, parallel group, placebo controlled study, including an additional open label tiotropium group, to assess the efficacy, safety and tolerability of 4 doses of AD 237 inhaled once daily for 28 days in subjects with COPD [chronic obstuctive pulmonary disease],
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Glycopyrrolate (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Sosei R&D
- 14 Dec 2005 New trial record.